In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an ...

Avanza Fonder AB bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The fund ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

1 Day AUTL -1.35% DJIA 1.24% Russell 2K 1.85% Health Care/Life Sciences -1.75% ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces ...